Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

Autor: Sissung TM; Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Rockville, MD, USA., McKeeby JW; Department of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA., Patel J; Pharmacy Department, NIH Clinical Center, Bethesda, MD, USA., Lertora JJ; Clinical Pharmacology Program (2006-2016), NIH Clinical Center, Bethesda, MD, USA., Kumar P; Clinical Pharmacokinetics Research Laboratory, NIH Clinical Center, Bethesda, MD, USA., Flegel WA; Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA., Adams SD; Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA., Eckes EJ; Medical Surgical Specialties Service, Clinical Center Nursing Department, NIH, Bethesda, MD, USA., Mickey F; Department of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA., Plona TM; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Mellot SD; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Baugher RN; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Wu X; Genomics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Soppet DR; Genomics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Barcus ME; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Datta V; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; Molecular Characterization Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Pike KM; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., DiPatrizio G; Department of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA., Figg WD; Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Rockville, MD, USA., Goldspiel BR; Pharmacy Department, NIH Clinical Center, Bethesda, MD, USA.
Jazyk: angličtina
Zdroj: Journal of clinical pharmacology [J Clin Pharmacol] 2017 Oct; Vol. 57 Suppl 10, pp. S67-S77.
DOI: 10.1002/jcph.993
Abstrakt: The National Institutes of Health Clinical Center (NIH CC) is the largest hospital in the United States devoted entirely to clinical research, with a highly diverse spectrum of patients. Patient safety and clinical quality are major goals of the hospital, and therapy is often complicated by multiple cotherapies and comorbidities. To this end, we implemented a pharmacogenomics program in 2 phases. In the first phase, we implemented genotyping for HLA-A and HLA-B gene variations with clinical decision support (CDS) for abacavir, carbamazepine, and allopurinol. In the second phase, we implemented genotyping for drug-metabolizing enzymes and transporters: SLCO1B1 for CDS of simvastatin and TPMT for CDS of mercaptopurine, azathioprine, and thioguanine. The purpose of this review is to describe the implementation process, which involves clinical, laboratory, informatics, and policy decisions pertinent to the NIH CC.
(© 2017, The American College of Clinical Pharmacology.)
Databáze: MEDLINE
Externí odkaz: